NCT04940299
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 10 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Stopped Trial terminated Sponsor's reason: \<75% participation
- Primary completion date changed from estimate of Dec 31, 2027 to Nov 11, 2026
- Notable Eligibility criteria shortened, about 6 words
- Secondary endpoints: details revised at 3 of 3 entries
- Study description revised
- Publications: details revised at 2 of 2 entries
- Notable Primary and study completion dates: Dec 31, 2025 to Dec 31, 2027v11
- Notable Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025v9
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 55 to confirmed 35
- Site details revised
Show 4 earlier versionsHide 4 earlier versions
- Notable Eligibility criteria expanded, about 4 words
- Study description expanded, about 66 words
- Notable Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024
- Eligibility criteria expanded, about 64 words
- Notable Primary and study completion dates: Jun 30, 2023 to Dec 31, 2023v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Nov 5, 2021 to Sep 23, 2021
- Site details revised
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Patients with melanoma will receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment with ipilimumab and nivolumab repeats every 3 weeks for 4 doses, then treatment with nivolumab repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Cohort 1 will be divided into 2 sub-groups: sub-group 1 of 25 patients, and subgroup 2 of 10 patients that will consist of varying Tocilizumab administration doses. For sub-group 1, Tocilizumab 162mg will be administered subcutaneously every 2 weeks starting week 0, up to 12 weeks for a total of 6 doses. For sub-group 2 , Tocilizumab 162mg will be administered subcutaneously once every week starting at week 0 up to week 6 followed by Tocilizumab administered subcutaneously every 2 weeks starting at week 6 up to 12 weeks for a total of 9 doses.
Patients with urothelial cancer will receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment with ipilimumab and nivolumab repeats every 3 weeks for 4 doses, then treatment with nivolumab repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Starting on week 1, patients also receive tocilizumab SC every 2 weeks for up to 12 weeks (6 doses) in the absence of disease progression or unacceptable toxicity.
Patients with NSCLC receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 2 weeks for up to 2 years. Patients also receive tocilizumab SC every 2 weeks for up to 12 weeks (6 doses). Treatment continues in the absence of disease progression or unacceptable toxicity.
Biologicals: Ipilimumab, Nivolumab, Tocilizumab
Sites
1 site in 1 country
- M D Anderson Cancer CenterHouston, Texas, United States